Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

THOUSAND OAKS, Calif., June 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive acute...

from PR Newswire: https://prn.to/2wXPDDQ